Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2020, 45(2): 99
ISSN 0377-8282
Copyright 2020 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2020.45.2.3093449
Trilaciclib hydrochloride. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, Myelopreservation therapy, Treatment of small cell lung cancer, Treatment of triple-negative breast cancer
Barquero, N.
Cancer is a worldwide prevalent disease that affects or will affect most adults at some point in their lives. Chemotherapy together with radiotherapy and surgery have been the main treatments against cancer. Chemotherapy, with its cytotoxic effects, is a powerful tool to defeat this disease, but in recent years there has been significant progress in the development of new therapies in this line of treatment. In addition, cytotoxic treatments produce strong secondary effects and therapies that revert or prevent these effects have become more necessary. In this sense, trilaciclib (G1T28), a novel experimental therapeutic drug, has shown promising results. This new compound is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) that reduces hematopoietic stem and progenitor cell death and therefore may reduce chemotherapy induced myelosuppression associated with most cytotoxic anticancer agents. Preclinical and clinical studies have revealed trilaciclib's ability to protect against myelosuppression associated with chemotherapy treatments. A reduction in clinical signs associated with myelosuppression induced by chemotherapy has been observed in patients treated with this new compound. Trilaciclib is still in early phases of clinical development, but results have thus far been very promising.

Full Text: PDF 

© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy